These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 26232492)

  • 41. Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer.
    Xing P; Wang H; Yang S; Han X; Sun Y; Shi Y
    BMC Immunol; 2018 Apr; 19(1):14. PubMed ID: 29661145
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future.
    Steendam CM; Dammeijer F; Aerts JGJV; Cornelissen R
    Immunotherapy; 2017 May; 9(6):507-520. PubMed ID: 28472903
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Melanoma-associated antigen-A3 vaccination in the treatment of non-small-cell lung cancer.
    Adam V; Wauters I; Vansteenkiste J
    Expert Opin Biol Ther; 2014 Mar; 14(3):365-76. PubMed ID: 24456101
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Is vaccine therapy a renewed strategic approach for non-small-cell lung cancer therapy?
    Rossi A
    Expert Rev Vaccines; 2013 Jan; 12(1):5-7. PubMed ID: 23256734
    [No Abstract]   [Full Text] [Related]  

  • 45. Next generation of immunotherapy for melanoma.
    Kirkwood JM; Tarhini AA; Panelli MC; Moschos SJ; Zarour HM; Butterfield LH; Gogas HJ
    J Clin Oncol; 2008 Jul; 26(20):3445-55. PubMed ID: 18612161
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy.
    Tyagi P; Mirakhur B
    Clin Lung Cancer; 2009 Sep; 10(5):371-4. PubMed ID: 19808198
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vaccine immunotherapy in lung cancer: Clinical experience and future directions.
    Freeman-Keller M; Goldman J; Gray J
    Pharmacol Ther; 2015 Sep; 153():1-9. PubMed ID: 25989231
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Active, specific immunotherapy for lung cancer: hurdles and strategies using genetic modification.
    Korst RJ; Crystal RG
    Ann Thorac Surg; 2003 Oct; 76(4):1319-26. PubMed ID: 14530047
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immune modulation as a therapeutic strategy for non-small-cell lung cancer.
    Holt GE; Disis ML
    Clin Lung Cancer; 2008 Feb; 9 Suppl 1():S13-9. PubMed ID: 18540530
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
    Sgambato A; Casaluce F; Gridelli C
    Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients.
    Segatori VI; Cuello HA; Gulino CA; Albertó M; Venier C; Guthmann MD; Demarco IA; Alonso DF; Gabri MR
    Cancer Immunol Immunother; 2018 Aug; 67(8):1285-1296. PubMed ID: 29936534
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Advances in immunotherapy for non-small cell lung cancer.
    Reckamp KL
    Clin Adv Hematol Oncol; 2015 Dec; 13(12):847-53. PubMed ID: 27058851
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ubiquitinated Proteins Isolated From Tumor Cells Are Efficient Substrates for Antigen Cross-Presentation.
    Yu G; Moudgil T; Cui Z; Mou Y; Wang L; Fox BA; Hu HM
    J Immunother; 2017 Jun; 40(5):155-163. PubMed ID: 28368960
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunotherapies for non-small-cell lung cancer and mesothelioma.
    Thomas A; Hassan R
    Lancet Oncol; 2012 Jul; 13(7):e301-10. PubMed ID: 22748269
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine.
    Tagliamento M; Rijavec E; Barletta G; Biello F; Rossi G; Grossi F; Genova C
    Expert Opin Biol Ther; 2018 Jul; 18(7):829-835. PubMed ID: 29936901
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use?
    Strioga MM; Darinskas A; Pasukoniene V; Mlynska A; Ostapenko V; Schijns V
    Vaccine; 2014 Jul; 32(32):4015-24. PubMed ID: 24837511
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel targeted agents for lung cancer.
    West HJ
    Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S41-6. PubMed ID: 19362946
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Frequent T cell responses against immunogenic targets in lung cancer patients for targeted immunotherapy.
    Babiak A; Steinhauser M; Götz M; Herbst C; Döhner H; Greiner J
    Oncol Rep; 2014 Jan; 31(1):384-90. PubMed ID: 24154794
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Molecular biology of lung cancer series].
    Hiret S; Senellart H; Bennouna J
    Rev Mal Respir; 2010 Oct; 27(8):954-8. PubMed ID: 20965409
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer.
    Pennell NA
    Semin Oncol; 2015 Oct; 42 Suppl 2():S3-10. PubMed ID: 26477472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.